Evidence has shown that high triglycerides are causally related to cardiovascular disease (CVD), and so drug therapy targeting this lipid abnormality could help to further reduce CVD risk in people with type 2 diabetes mellitus (T2DM). Fibrates are an example of such a drug therapy, as they both decrease triglyceride levels and increase high-density lipoproteins (HDL) cholesterol. 

A beneficial reduction in major CVD events was shown in a pre-specified sub-group of participants with dyslipidaemia

Please sign in to read more